Technology
Health
Biotechnology

BioXcel Therapeutics

$10.18
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.
9
8
7
6
5
4
3
2
1
0
-
$
,
.

-$0.15 (-1.45%) Today
-$0.15 (-1.45%) Today

Why Robinhood?

You can buy or sell BTAI and other stocks, options, ETFs, and crypto commission-free!

About

BioXcel Therapeutics, Inc. Common Stock, also called BioXcel Therapeutics, is a clinical stage biopharmaceutical company focuses on drug development. Read More The firm's two clinical development programs are BXCL501, a sublingual thin film formulation designed for acute treatment of agitation resulting from neurological and psychiatric disorders, and BXCL701, an immuno-oncology agent designed for treatment of a rare form of prostate cancer and for treatment of pancreatic cancer. The company was founded by Vimal D. Mehta on March 29, 2017 and is headquartered in New Haven, CT.

Employees
18
Headquarters
New Haven, Connecticut
Founded
2017
Market Cap
161.80M
Price-Earnings Ratio
β€”
Dividend Yield
β€”
Average Volume
66.63K
High Today
$10.42
Low Today
$10.14
Open Price
$10.42
Volume
12.86K
52 Week High
$14.79
52 Week Low
$2.41

Collections

Technology
Health
Biotechnology
Medical
Therapy
Biopharmaceutical
Cancer Prevention
Pharmaceutical

News

Simply Wall StMar 14

What Kind Of Shareholder Owns Most BioXcel Therapeutics, Inc. (NASDAQ:BTAI) Stock?

A look at the shareholders of BioXcel Therapeutics, Inc. (NASDAQ:BTAI) can tell us which group is most powerful. Institutions often own shares in more established companies, while it’s not unusual to see insiders own a fair bit of smaller companies. We also tend to see lower insider ownership in companies that were previously publicly owned. With a market capitalization of US$146m, BioXcel Therapeutics is a small cap stock, so it might not be well known by many institutional investors. Taking a look at our...

80
Markets InsiderMar 8

This Day That Year: BioXcel Therapeutics

(RTTNews) - Shares of BioXcel Therapeutics Inc. (BTAI) are down nearly 47% from their all-time high of $14.79 recorded on July 10, 2018. It was on this day last year, i.e. on March 8, 2018, that BioXcel debuted on the NASDAQ Capital Market by setting a public offering at $11 per share. BioXcel Therapeutics is a clinical-stage biopharmaceutical company focused on drug development that utilizes novel artificial intelligence to identify the next wave of medicines across neuroscience and immuno-oncology. The...

5
Seeking AlphaMar 7

BioXcel Therapeutics, Inc. (BTAI) CEO Vimal Mehta on Q4 2018 Results - Earnings Call Transcript

BioXcel Therapeutics (NASDAQ:BTAI) Q4 2018 Earnings Conference Call March 7, 2019 8:30 AM ET Company Participants Carol Ruth - Founder and President, The Ruth Group Vimal Mehta - Founder, Chief Executive Officer, President, Secretary and Director Richard Steinhart - Chief Financial Officer Vincent O'Neill - Senior Vice President and Chief Medical Officer Frank Yocca - Chief Scientific Officer Conference Call Participants Scott Puckhaber - Barclays Keith Tapper - BMO Capital Markets Ram Selvaraju -...

37

Earnings

-$0.46
-$0.37
-$0.28
-$0.19
Q1 2018
Q2 2018
Q3 2018
Q4 2018
Estimated
-$0.39 per share
Actual
-$0.46 per share
All investments involve risk and the past performance of a security, or financial product does not guarantee future results or returns. Securities offered through Robinhood Financial LLC, member FINRA/SIPC. To learn more about the information provided on this page, please see our Web Disclosures.